MA02.06 Efficacy and Safety of 1L Olomorasib Plus Pembrolizumab in KRAS G12C-Mutant NSCLC: Results From LOXO-RAS-20001 and SUNRAY-01
M.L. Johnson, Leticia Léon Mateos, Tadaaki Yamada, Neeharika Srivastava Makani, Brian Chan, Wentao Huang, Dionysios Spyratos, J. Roubec, N. Reinmuth, A. Sacher, A. Spira, N. Singhal, Shinji Takeuchi, Yonina R. Murciano‐Goroff, Yi Zhou, Aaron Alan Fink, A. Merced, M.D. Willard, Carla Visseren‐Grul, S. Peters
Topics & Concepts
MedicinePembrolizumabKRASInternal medicineOncologyMEDLINEImmunotherapyPD-L1Cancer researchAdverse effectCancer Immunotherapy and BiomarkersColorectal Cancer Treatments and StudiesGenetic factors in colorectal cancer